Moreover, there was no significant difference in CSPG4 expression in EVs isolated from serum of patients with EGFR T790M positive or negative tumours at study inclusion (Figures 4B and S6B), nor was there a significant change in CSPG4 expression levels between baseline and progression that could be linked to the individual patient outcome, that is, PFS or OS (Figures 4C and S6C). The gene discussed is EGFR; the disease is neoplasm.